Linked Life Data

6165466

Source:http://linkedlifedata.com/resource/pubmed/id/6165466

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3-4
pubmed:dateCreated
1981-8-20
pubmed:abstractText
Doxorubicin and dactinomycin were administered to 25 patients with advanced sarcomas. Twenty-one were evaluable for response. There were six responses (two complete and four partial) (28%) and eight improvements. Responders survived longer than nonresponders, while those with improvements had intermediate survival. Toxic effects included leukopenia in 35% of administered courses, mucositis in 50% of the patients, and congestive heart failure in 21% of the patients. Plasma doxorubicin kinetics did not correlate with excess toxic effects in four patients studied. The response rates and durations of survival obtained with this combination are comparable to those obtained with doxorubicin alone. The marked increase in toxicity makes this combination less desirable than treatment with doxorubicin alone.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0361-5960
pubmed:author
pubmed:issnType
Print
pubmed:volume
65
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
231-6
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:articleTitle
Doxorubicin and dactinomycin therapy for advanced sarcomas.
pubmed:publicationType
Journal Article